Bladder urothelial and bladder cancer cells

Bladder urothelial cells constitute the specialized epithelial lining of the urinary bladder, known as the urothelium, which serves as a critical blood-urine barrier and a transducer of mechanical stimuli (Birder & Andersson, 2013). Bladder cancer cells, primarily representing urothelial carcinoma, are the malignant counterparts that arise from genetic alterations in these cells, such as mutations in FGFR3, PIK3CA, or TP53 (Netto, 2011). While these cells are the primary focus of bladder cancer therapy, they do not represent a single molecular target; instead, they are a complex cellular population expressing various druggable receptors and enzymes. Modern therapeutic strategies target specific molecules on these cells, such as Nectin-4 with antibody-drug conjugates like Enfortumab vedotin, or FGFR3 with kinase inhibitors like Erdafitinib (Powles et al., 2021). Understanding the biological landscape of these cells is essential for the development of targeted therapies and immunotherapies in the management of urothelial malignancies (NIH, 2023).

Other names

Urothelial cellsBladder cancer cellsUrotheliumTransitional cell carcinoma cellsUCC cells

Not applicable as this is a cell type/disease state rather than a specific molecular target. Drugs listed interact with specific proteins expressed by these cells, such as PD-1/PD-L1, Nectin-4, FGFR3, or TROP-2.